LDLR-targeted orlistat therapeutic nanoparticles: Peptide selection, assembly, characterization, and cell-uptake in breast cancer cell lines
(2025)
Journal Article
Bebawy, G., Collier, P., Williams, P. M., Burley, J. C., & Needham, D. (2025). LDLR-targeted orlistat therapeutic nanoparticles: Peptide selection, assembly, characterization, and cell-uptake in breast cancer cell lines. International Journal of Pharmaceutics, 676, Article 125574. https://doi.org/10.1016/j.ijpharm.2025.125574
Motivation: Many cancers overexpress low-density lipoprotein receptors (LDLR), facilitating cholesterol metabolism for tumour growth. Targeting LDLR offers a promising strategy for selective drug delivery. Orlistat, a fatty acid synthase (FAS) inhibi... Read More about LDLR-targeted orlistat therapeutic nanoparticles: Peptide selection, assembly, characterization, and cell-uptake in breast cancer cell lines.